Latest Research And Development News

Vection Technologies has successfully raised $3.55 million, exceeding its initial $2 million target, following a robust Q3 FY25 performance marked by a 92% increase in cash receipts and a significant boost in recurring revenue.

LTR Pharma reports strong Q1 2025 progress with FDA pre-IND meeting success, scientific acclaim for SPONTAN’s rapid absorption, and strategic launch of ROXUS to fast-track US market entry.

Mach7 Technologies reported a robust Q3 FY25 with a CARR of A$30.8 million and positive operating cash flow, while announcing a leadership change and reaffirming growth guidance.

Titomic Limited has entered a strategic teaming agreement with REPKON USA to jointly develop and apply its kinetic fusion cold spray technology for advanced defense manufacturing, focusing on repairs and performance enhancements of critical military assets.

Knosys Limited reports a record Annual Recurring Revenue run rate of $9.8 million, driven by strong enterprise renewals and new customer wins, alongside the launch of its next-generation Libero library app and upgraded LMS.

Sprintex Limited has advanced its commercial and technological milestones with major European and Indian orders, breakthrough energy efficiency validation, and a successful A$3.25 million equity raise, positioning the company for accelerated growth.

Jindalee Lithium’s McDermitt Lithium Project has been designated a FAST-41 Transparency Project, enhancing federal permitting visibility and coordination to accelerate development in the US critical minerals sector.

Deep Yellow Ltd disclosed a quarterly cash flow report for Q1 2025, revealing a significant operating cash outflow but a robust cash reserve that supports an estimated 20 quarters of funding runway.

Nyrada Inc. posted a significant $2.46 million loss for H1 FY25, driven by increased R&D spend, while advancing its lead drug NYR-BI03 into first-in-human trials following regulatory approval.

Zelira Therapeutics has received a $1.15 million cash refund from the Australian Government’s R&D Tax Incentive Scheme, bolstering its working capital to advance clinical development and business operations.

Infomedia Ltd reported a solid half-year performance with a 2% revenue increase and a 63% surge in net profit, while announcing a strategic acquisition and a share buyback plan.

Neurizon Therapeutics reported a sharp rise in half-year losses to $7.28 million but marked significant progress with its lead drug NUZ-001 entering a major ALS clinical trial and securing critical regulatory designations.